1. Home
  2. SANA vs AURA Comparison

SANA vs AURA Comparison

Compare SANA & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sana Biotechnology Inc.

SANA

Sana Biotechnology Inc.

N/A

Current Price

$2.01

Market Cap

688.5M

Sector

Health Care

ML Signal

N/A

Logo Aura Biosciences Inc.

AURA

Aura Biosciences Inc.

N/A

Current Price

$7.11

Market Cap

631.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SANA
AURA
Founded
2018
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
688.5M
631.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
SANA
AURA
Price
$2.01
$7.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
6
Target Price
$8.43
★ $16.60
AVG Volume (30 Days)
★ 2.6M
748.9K
Earning Date
11-05-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 17.24
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$4.73
52 Week High
$5.49
$9.54

Technical Indicators

Market Signals
Indicator
SANA
AURA
Relative Strength Index (RSI) 32.21 57.34
Support Level N/A $6.65
Resistance Level $3.41 $7.83
Average True Range (ATR) 0.19 0.41
MACD -0.02 0.11
Stochastic Oscillator 15.96 60.05

Price Performance

Historical Comparison
SANA
AURA

About SANA Sana Biotechnology Inc.

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Share on Social Networks: